Theyll assess your medical history and individual circumstances and either issue your prescription or recommend an alternative weight loss treatment
This commitment to transparent and responsibly-sourced ingredients helps us maintain our devotion to Compounding with Integrity
1,4 Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic injection in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic 0.5 mg + basal insulin MET 10.7% with Ozempic 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic injection in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 Adverse events 5% in SUSTAIN FORTE 4 AEs occurring in 5% of patients receiving Ozempic injection 1 mg and 2 mg in SUSTAIN FORTE In placebo-controlled trials, the most common adverse reactions reported in 5% of patients treated with Ozempic injection are nausea, vomiting, diarrhea, abdominal pain, and constipation 1 No new safety signals were identified
Standard dose escalation: 0.25 mg weekly for 4 weeks 0.5 mg weekly for 4+ weeks 1.0 mg weekly for 4+ weeks 1.7 mg weekly if needed 2.4 mg weekly (maximum) There is no requirement to reach 2.4 mg if the patient is responding and tolerating treatment
Dr Winnett and his team help patients explore all evidence-based weight-management options, including medication, endoscopic procedures, and bariatric surgery
